Protein redistribution diet remains effective in patients with fluctuating parkinsonism
- PMID: 1736847
- DOI: 10.1001/archneur.1992.00530260049018
Protein redistribution diet remains effective in patients with fluctuating parkinsonism
Abstract
Forty-three carbidopa-levodopa (Sinemet)-treated parkinsonian patients with protein-sensitive motor fluctuations were started on the protein redistribution diet within the past 48 months. Thirty patients (70%) are still using the diet successfully after more than 12 months (mean duration, 33.6 months; range, 12 to 48 months). The diet was discontinued in the other 13 cases. In 10 of these 13 patients, the protein redistribution diet was discontinued for a variety of reasons, despite continued sensitivity to dietary protein; in only three patients (7%), those with the most severe and complicated disease, was the protein redistribution diet stopped because of its limited therapeutic benefit. The protein redistribution diet is a simple adjunct to the treatment of Parkinson's disease that can significantly prolong the efficacy of levodopa therapy in many fluctuating "end-stage" patients.
Similar articles
-
Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report.Arch Neurol. 1991 Apr;48(4):402-5. doi: 10.1001/archneur.1991.00530160070016. Arch Neurol. 1991. PMID: 2012514 Clinical Trial.
-
Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.Neurology. 1987 Feb;37(2):233-41. doi: 10.1212/wnl.37.2.233. Neurology. 1987. PMID: 3808304
-
Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.Clin Neuropharmacol. 1988 Apr;11(2):168-73. Clin Neuropharmacol. 1988. PMID: 3378225
-
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.Neurology. 1989 Nov;39(11 Suppl 2):7-10; discussion 19. Neurology. 1989. PMID: 2685653 Review.
-
Medical treatment of Parkinson's disease.Compr Ther. 1989 Mar;15(3):53-9. Compr Ther. 1989. PMID: 2650977 Review. No abstract available.
Cited by
-
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.Clin Pharmacokinet. 2002;41(4):261-309. doi: 10.2165/00003088-200241040-00003. Clin Pharmacokinet. 2002. PMID: 11978145 Review.
-
Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.Front Aging Neurosci. 2017 Jun 28;9:206. doi: 10.3389/fnagi.2017.00206. eCollection 2017. Front Aging Neurosci. 2017. PMID: 28701947 Free PMC article. Review.
-
Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review.Adv Nutr. 2021 Dec 1;12(6):2265-2287. doi: 10.1093/advances/nmab060. Adv Nutr. 2021. PMID: 34113965 Free PMC article.
-
Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease.J Clin Mov Disord. 2016 May 26;3:8. doi: 10.1186/s40734-016-0036-9. eCollection 2016. J Clin Mov Disord. 2016. PMID: 27231577 Free PMC article.
-
Assessment of body composition, sarcopenia and protein intake in mild to moderate Parkinson's disease.Front Nutr. 2025 Jul 7;12:1507545. doi: 10.3389/fnut.2025.1507545. eCollection 2025. Front Nutr. 2025. PMID: 40693199 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous